Coenzyme Q10 and spinocerebellar ataxias
dc.contributor.author | Lo, Raymond Y. | en_US |
dc.contributor.author | Figueroa, Karla P. | en_US |
dc.contributor.author | Pulst, Stefan M. | en_US |
dc.contributor.author | Lin, Chi‐ying | en_US |
dc.contributor.author | Perlman, Susan | en_US |
dc.contributor.author | Wilmot, George | en_US |
dc.contributor.author | Gomez, Christopher | en_US |
dc.contributor.author | Schmahmann, Jeremy | en_US |
dc.contributor.author | Paulson, Henry | en_US |
dc.contributor.author | Shakkottai, Vikram G. | en_US |
dc.contributor.author | Ying, Sarah | en_US |
dc.contributor.author | Zesiewicz, Theresa | en_US |
dc.contributor.author | Bushara, Khalaf | en_US |
dc.contributor.author | Geschwind, Michael | en_US |
dc.contributor.author | Xia, Guangbin | en_US |
dc.contributor.author | Subramony, S.H. | en_US |
dc.contributor.author | Ashizawa, Tetsuo | en_US |
dc.contributor.author | Kuo, Sheng‐han | en_US |
dc.date.accessioned | 2015-03-05T18:24:19Z | |
dc.date.available | 2016-04-01T15:21:06Z | en |
dc.date.issued | 2015-02 | en_US |
dc.identifier.citation | Lo, Raymond Y.; Figueroa, Karla P.; Pulst, Stefan M.; Lin, Chi‐ying ; Perlman, Susan; Wilmot, George; Gomez, Christopher; Schmahmann, Jeremy; Paulson, Henry; Shakkottai, Vikram G.; Ying, Sarah; Zesiewicz, Theresa; Bushara, Khalaf; Geschwind, Michael; Xia, Guangbin; Subramony, S.H.; Ashizawa, Tetsuo; Kuo, Sheng‐han (2015). "Coenzyme Q10 and spinocerebellar ataxias." Movement Disorders 30(2): 214-220. | en_US |
dc.identifier.issn | 0885-3185 | en_US |
dc.identifier.issn | 1531-8257 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/110713 | |
dc.description.abstract | The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC‐SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS‐IV), and the 9‐item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross‐sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS‐IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS‐IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association. © 2014 International Parkinson and Movement Disorder Society | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | spinocerebellar ataxias | en_US |
dc.subject.other | coenzyme Q10 | en_US |
dc.subject.other | statins | en_US |
dc.subject.other | neurodegeneration | en_US |
dc.title | Coenzyme Q10 and spinocerebellar ataxias | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/110713/1/mds26088.pdf | |
dc.identifier.doi | 10.1002/mds.26088 | en_US |
dc.identifier.source | Movement Disorders | en_US |
dc.identifier.citedreference | Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2‐year follow‐up study. Neurology 2011; 77: 1035 – 1041. | en_US |
dc.identifier.citedreference | Schmitz‐Hübsch T, Montcel du ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006; 66: 1717 – 1720. | en_US |
dc.identifier.citedreference | Dürr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010; 9: 885 – 894. | en_US |
dc.identifier.citedreference | Simon DK, Zheng K, Velázquez L, et al. Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. Arch Neurol 2007; 64: 1042 – 1044. | en_US |
dc.identifier.citedreference | Wang HL, Chou AH, Lin AC, Chen SY, Weng YH, Yeh TH. Polyglutamine‐expanded ataxin‐7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons. Exp Neurol 2010; 224: 486 – 494. | en_US |
dc.identifier.citedreference | Ashizawa T, Figueroa KP, Perlman SL, et al. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis 2013; 8: 177. | en_US |
dc.identifier.citedreference | de Castilhos RM, Furtado GV, Gheno TC, et al. Spinocerebellar ataxias in brazil‐frequencies and modulating effects of related genes. Cerebellum 2014; 13: 17 – 28. | en_US |
dc.identifier.citedreference | Schöls L, Amoiridis G, Büttner T, Przuntek H, Epplen JT, Riess O. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997; 42: 924 – 932. | en_US |
dc.identifier.citedreference | Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007; 7 ( Suppl ): S168 – S174. | en_US |
dc.identifier.citedreference | Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117 – 125. | en_US |
dc.identifier.citedreference | Schmitz‐Hübsch T, Coudert M, Tezenas du Montcel S, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011; 26: 870 – 876. | en_US |
dc.identifier.citedreference | Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double‐blind, placebo‐controlled pilot trial. Neurology 2010; 74: 839 – 845. | en_US |
dc.identifier.citedreference | Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012; 78: 545 – 550. | en_US |
dc.identifier.citedreference | Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. New Engl J Med 2012; 366: 636 – 646. | en_US |
dc.identifier.citedreference | Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002; 33: 182 – 191. | en_US |
dc.identifier.citedreference | Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat Rev Neurol 2011; 7: 561 – 572. | en_US |
dc.identifier.citedreference | Lee YC, Lin CH, Wu RM, et al. Discontinuation of statin therapy associates with Parkinson disease: a population‐based study. Neurology 2013; 81: 410 – 416. | en_US |
dc.identifier.citedreference | Pac‐Soo C, Lloyd DG, Vizcaychipi MP, Ma D. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 2011; 27: 1 – 10. | en_US |
dc.identifier.citedreference | Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011; 230: 27 – 34. | en_US |
dc.identifier.citedreference | Underwood BR, Rubinsztein DC. Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies. Cerebellum 2008; 7: 215 – 221. | en_US |
dc.identifier.citedreference | Dueñas AM, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain 2006; 129: 1357 – 1370. | en_US |
dc.identifier.citedreference | Pineda M, Montero R, Aracil A, et al. Coenzyme Q(10)‐responsive ataxia: 2‐year‐treatment follow‐up. Mov Disord 2010; 25: 1262 – 1268. | en_US |
dc.identifier.citedreference | Artuch R, Brea‐Calvo G, Briones P, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow‐up after coenzyme Q10 supplementation. J Neurol Sci 2006; 246: 153 – 158. | en_US |
dc.identifier.citedreference | Chou AH, Lin AC, Hong KY, et al. p53 activation mediates polyglutamine‐expanded ataxin‐3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neuroch Int 2011; 58: 145 – 152. | en_US |
dc.identifier.citedreference | Wang HL, Yeh TH, Chou AH, et al. Polyglutamine‐expanded ataxin‐7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl‐x(L). Cell Signal 2006; 18: 541 – 552. | en_US |
dc.identifier.citedreference | Chou AH, Yeh TH, Kuo YL, et al. Polyglutamine‐expanded ataxin‐3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl‐xL. Neurobiol Dis 2006; 21: 333 – 345. | en_US |
dc.identifier.citedreference | Sánchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase‐8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999; 22: 623 – 633. | en_US |
dc.identifier.citedreference | Schmitz‐Hübsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010; 74: 678 – 684. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.